◼ Archived
Business
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
Moderna shares surge toward a 52-week high as upcoming melanoma vaccine data commands attention at the ESMO Congress.
Esmo Congress
1 trends tracked about this subject — the full history, oldest to newest below.